Chloroquine phosphate contraindications: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Chloroquine phosphate}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CHLOROQUINE (CHLOROQUINE PHOSPHAT..." |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Contraindications== | |||
Use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to any other etiology, and in patients with known hypersensitivity to 4-aminoquinoline compounds. However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, the physician may elect to use this drug after carefully weighing the possible benefits and risks to the patient.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CHLOROQUINE (CHLOROQUINE PHOSPHATE) TABLET CHLOROQUINE (CHLOROQUINE PHOSPHATE) TABLET, COATED [WEST-WARD PHARMACEUTICAL CORP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b585ad5-ae86-4403-b83f-8d8363d43da5 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CHLOROQUINE (CHLOROQUINE PHOSPHATE) TABLET CHLOROQUINE (CHLOROQUINE PHOSPHATE) TABLET, COATED [WEST-WARD PHARMACEUTICAL CORP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b585ad5-ae86-4403-b83f-8d8363d43da5 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 18:38, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Contraindications
Use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to any other etiology, and in patients with known hypersensitivity to 4-aminoquinoline compounds. However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, the physician may elect to use this drug after carefully weighing the possible benefits and risks to the patient.[1]
References
Adapted from the FDA Package Insert.